Ozempic Maker Novo Nordisk Launches Next-Gen Weight Loss Drug With 25% More Efficacy
Novo Nordisk unveiled CagriSema, a combination therapy that showed 25.4% average weight loss in Phase 3 trials, surpassing current GLP-1 drugs. The company's market capitalization briefly exceeded $700 billion on the announcement.
Novo Nordisk unveiled CagriSema, a combination therapy that showed 25.4% average weight loss in Phase 3 trials, surpassing current GLP-1 drugs. The company's market capitalization briefly exceeded $700 billion on the announcement.
Related Articles
Breakthrough mRNA Cancer Vaccine Shows 67% Tumor Reduction in Phase 3 Trial
Moderna and Merck reported that their personalized mRNA cancer vaccine reduced tumor recurrence by 67% in advanced melanoma patients during a pivotal Phase 3 trial, potentially opening a new era in oncology treatment.
Dr. Amanda Foster·13h ago
WHO Declares New Mpox Variant a Global Health Emergency
The World Health Organization activated its highest alert level after a new mpox variant showed increased transmissibility across 14 countries. Health agencies worldwide are accelerating vaccine distribution and surveillance protocols.
Dr. Amanda Foster·22h ago
Comments(0)
No comments yet. Be the first to share your thoughts.